CASC3 and mantle cell lymphoma: BTZ was approved by the FDA in 2003, for the treatment of relapsed/refractory multiple myeloma (MM), in 2006, for the treatment of refractory/relapsed mantle cell lymphoma, and, in 2014, for previously untreated mantle cell lymphoma (44).